Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
HyperaFRA:HM6A -13.20%73 EV-to-EBITDA is 6.89 as of Aug. 31, 2026, which is 49% below its 10-year median of 13.61. GuruFocus rates FRA:HM6A with a GF Score™ of 73/100 and a GF Value™ of €5.33 (Possible Value Trap). The stock has 4 warning signs investors should review. Among 730 Drug Manufacturers companies, Hypera ranks better than 76.85% on this metric.
EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Hypera's enterprise value is €3,389 Mil.
Hypera's EBITDA for the trailing twelve months (TTM) ended in Jun. 2026 was €492 Mil. Therefore, Hypera's EV-to-EBITDA for today is 6.89.
The historical rank and industry rank for Hypera's EV-to-EBITDA or its related term are showing as below:
FRA:HM6A'
s EV-to-EBITDA Range Over the Past 10 Years
Min: 6.4 Med: 13.61 Max: 20.47
Current: 6.91
During the past 13 years, the highest EV-to-EBITDA of Hypera was 20.47. The lowest was 6.40. And the median was 13.61.
FRA:HM6A's EV-to-EBITDA is ranked better than 76.85% of 730
companies
in the Drug Manufacturers industry
Industry Median: 13.47
vs FRA:HM6A: 6.91
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
As of today (2026-08-31), Hypera's stock price is €3.42.
Hypera's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2026 was €0.432. Therefore, Hypera's PE Ratio (TTM) for today is 7.92.
The "classic" EV-to-EBITDA is much better in capturing debt and net cash than the PE Ratio (TTM).
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Hypera's share price for today is €3.42.
Hypera's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €0.432.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio (TTM).
The historical data trend for Hypera's EV-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FRA:HM6A vs ZTS, UTHR, VTRS: EV-to-EBITDA Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Hypera's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Hypera EV-to-EBITDA vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Hypera's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Hypera's EV-to-EBITDA falls into.
Hypera's current Enterprise Value is €3,389 Mil.
Hypera's EBITDA for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €492 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Hypera (FRA:HM6A) has a EV-to-EBITDA of 6.89 as of Aug. 31, 2026. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Hypera. This is 49% below median its historical median of 13.61. Over the past decade, Hypera's EV-to-EBITDA has ranged from 6.40 to 20.47. According to the industry distribution chart, Hypera ranks #169 out of 730 companies in the Drug Manufacturers industry, placing it in the top 23.2%.
Is Hypera's EV-to-EBITDA too high?
Hypera's current EV-to-EBITDA of 6.89 is 49% below median its 10-year median of 13.61. Over the past 10 years, this metric has ranged from a low of 6.40 to a high of 20.47. The Drug Manufacturers industry median EV-to-EBITDA is 13.47. Hypera's value of 6.89 is 48.8% below this industry median. Based on the distribution chart, Hypera ranks #169 out of 730 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Hypera has a GF Score™ of 73/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Hypera's EV-to-EBITDA compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Hypera ranks #169 out of 730 companies for EV-to-EBITDA. This places Hypera in the top 23% of its industry — outperforming the majority of peers. The industry median EV-to-EBITDA is 13.47. Hypera's value of 6.89 is 48.8% below this benchmark. Historically, Hypera's own EV-to-EBITDA has ranged from 6.40 to 20.47 over the past decade. While the company's 10-year median is 13.61 vs. the industry median of 13.47, Hypera has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBITDA for a Drug Manufacturers company?
The median EV-to-EBITDA among Drug Manufacturers companies is 13.47, based on 730 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Hypera's current EV-to-EBITDA of 6.89 is 48.8% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBITDA mean?
A high EV-to-EBITDA can signal that a stock is expensive relative to its fundamentals. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Hypera. For the Drug Manufacturers industry, the median EV-to-EBITDA is 13.47 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Hypera's current EV-to-EBITDA is 6.89, which is 49% below median its own 10-year median of 13.61. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Hypera stock overvalued right now?
Based on GuruFocus' analysis, Hypera (FRA:HM6A) is currently considered Possible Value Trap. The stock's GF Value™ is €5.33, compared to a current price of €3.42 — trading 35.8% below its estimated fair value. The current EV-to-EBITDA is 6.89, which is 49% below median its 10-year median of 13.61 and 48.8% below the Drug Manufacturers industry median of 13.47. Hypera's overall GF Score™ is 73/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBITDA calculated?
EV-to-EBITDA is calculated from a company's financial statements. For Hypera (FRA:HM6A), the current EV-to-EBITDA is 6.89 as of Aug. 31, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Hypera (FRA:HM6A) Overvalued in 2026?
Based on GuruFocus' analysis, Hypera stock appears to be undervalued.
The current stock price of €3.42 is trading 35.8% below its estimated GF Value™ of €5.33.
GuruFocus considers Hypera to be Possible Value Trap.
Key valuation signals for FRA:HM6A:
EV-to-EBITDA: 6.89 (49% below median its 10-year median of 13.61)
GF Value™: €5.33 vs. price of €3.42 (35.8% below fair value)
Industry Position: 48.8% below the Drug Manufacturers median (#169 of 730)
No single metric tells the full story. See the FRA:HM6A stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Hypera SA is a specialty and generic drug manufacturing company. The company operates in the prescription medicines, over-the-counter (OTC) medicines, branded generics, and generics, and skincare segments within the retail pharmaceutical market. The company also has a wide sales and distribution structure. The company's product portfolio includes key brands in Gastroenterology, Pain, Sun Protection, Skin Moisture, and Cleansing within the over-the-counter (OTC) and Skincare segments, as well as new products in Cardiology, Central Nervous System, and Respiratory System within the prescription medicines segment.
73GF Score
Get the complete analysis for FRA:HM6A
EV-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:HM6A has been successfully added to your 
